



IBA Signs Final Contracts to Install Three Compact Proton Therapy Centers in the United Kingdom

**Contracts are based on previously announced letter of intent to install
three Proteus[®] ONE centers**

Louvain-la-Neuve, Belgium, November 13, 2015 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, has signed contracts with Proton Partners International (PPI) to install three *Proteus[®] ONE* compact proton therapy systems in private clinics in the United Kingdom: one in Newport (Wales), one in Newcastle (England) and a third location to be identified at a later stage.

The contracts, which were previously announced upon the signing of a letter of intent in an IBA press release dated June 25th 2015, will also include a long-term service agreement. The typical end-user price for a *Proteus[®] ONE* system with this service contract ranges between EUR 35 and 40 million.

These three projects are part of a framework agreement that IBA and Philips signed in September 2014 to advance the diagnosis and treatment of cancer and demonstrate the efficiency and potential of the collaboration between the two organizations.

Olivier Legrain, Chief Executive Officer of IBA, commented: "Proton Partners International's selection of IBA not only strengthens our world leading position in proton therapy, but also demonstrates the preference of IBA as the most experienced proton therapy provider in the market with the fastest delivery times. These contracts also demonstrate the potential of our collaboration with Philips as we look to bring cutting edge proton therapy to new regions."

Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "We are delighted to announce that we will be working with IBA, the world leader in proton therapy technology, who will equip our centres to the highest specifications. We are excited about the opportunity to deliver the first proton therapy centres in the UK and we look forward to working with a range of stakeholders to help support the research effort in the wider use of proton beam therapy for the benefit of the patients from all over UK."

Neil Mesher, Managing Director, Health Systems, Philips UK, added: "These new centers represent a major step forward in the delivery of care for oncology patients in the UK. We are delighted to be working with Proton Partners International and IBA which is strongly in line with our aim of improving people's lives through meaningful innovation."

- Ends -



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Proton Partners International Limited

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation's cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman, Professor Karol Sikora is Chief Medical Advisor and one of the Founders, Mike Moran has been appointed as the Chief Executive Officer. www.proton-int.com

IBA

Jean-Marc Bothy

Chief Financial Officer
Tel: +32 10 47 58 90

Thomas Ralet

Vice-President Corporate Communication
+32 10 47 58 90
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0)20 3709 5700
IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com